drugset
drugset / Trial / NCT00489294

Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency

NCT00489294 ↗

Phase 1 Completed 20 enrolled Phage Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics of Syntropin (a human growth hormone) and to determine the serum concentration of IGF-1 after Syntropin injection.

Timeline

Start
2004-08
Primary completion
2005-06
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Syntropin Protein / enzyme biologic — Subcutaneous

Indications

pituitary deficiency